Bronchitol sales just started not long ago.
Current approved market size (AU & EU for Adult) is only around $75m p.a, and only Germany & UK are on sale.
The market share for US and EU for children is around 4 times of current approved market share, being $290m.
In addition, the bronchiectasis could target a $800m market share, although trial III results were disappointed.
PXS is still a junior/developer, it can't be valued used PE ratio. Compared with other Bio juniors, QRX, PBT, PRR, TIS, all of them don't have any sales, but their individual E/V is much higher than PXS', basically PXS has no enterprise value at current market cap.
Bronchitol sales just started not long ago. Current approved...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
